SENSEX NIFTY

Taro

Nov 14, 2014 at 11:59 | Source: CNBC-TV18
The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.
Nov 13, 2014 at 17:33 | Source: CNBC-TV18
Sun Pharma for its second quarter ended September 2014 a net profit of Rs 1,362 crore during the same period of previous fiscal.
Nov 10, 2014 at 11:10 | Source: Moneycontrol.com
Taro's gross profit, as a percentage of net sales, was at 79 percent compared to 77.7 percent. During the quarter, operating income increased USD 40.0 million to USD 160.3 million, or 63.9 percent of net sales, compared to 58.6 percent of net sales.
Nov 10, 2014 at 10:00 | Source: Moneycontrol.com
Sun Pharma topped the buying list, up nearly 4 percent after Taro reported a 49 percent growth in Q2 profit and 22.2 percent jump in net sales.
Oct 11, 2014 at 14:53 | Source: Moneycontrol.com
Analysts at Motilal Oswal believe that Lupin, Ranbaxy, Cadila Healthcare, GSK Pharma, Torrent Pharma and Alembic Pharma will report stronger overall operational performance during this quarter.
Sep 12, 2014 at 13:42 | Source: Moneycontrol.com
Taro has recalled two lots of a key drug on September 2, citing failed content uniformity specifications, according to drug regulator. The drug contributes nearly 5 percent of Taro's sales, analysts say.
Sep 10, 2014 at 09:45 | Source: CNBC
The yen`s near-term outlook hinges on the direction of the US dollar, say analysts, who expect further downside in the Japanese currency.
Aug 13, 2014 at 15:33 | Source: CNBC-TV18
According to Uday Baldota, people should not focus too much on one-time sales of the company as Sun Pharma is confident of achieving its full year guidance.
Aug 11, 2014 at 17:40 | Source: CNBC-TV18
Revenue is seen going up by 17.5 percent to Rs 4,115 crore during the quarter from Rs 3,503 crore in the year-ago period driven by US sales.
Jun 30, 2014 at 13:38 | Source: Moneycontrol.com
Credit Suisse believes if price increase sustains, sales and EBITDA for Taro could increase by USD 300 million (or 70 percent increase from FY14 EBITDA) and have factored in only half of the price increase and wait for competition to react.
Messages on Taro »

maximindia

Platinum Member

607 Followers

Ranbaxy Labs  

One must understand that SUN cannot b redflagged bcs its main subsidiary is TARO is situated in Iserael which has more strintest practoces more than even USA.Also USA realised that by redflagging Indian cos like RBaxy it is USA public which is suffering bcs of nongen drugs produced by another

6.26 PM Jul 7th

shmarketgen
ius

Platinum Member

607 Followers

Suven Life Scie  

That`s also a good strategy.Something I hear/read,even RJ follows.SLS management is conservative & Mr. Jasti has always been very candid about his company.Recently,they had achieved aprroval for Malathion,to be marketed by Taro.The bottomline will be 2MUSD every year from this product alone! See

9.23 PM Jul 3rd

2sunilkamat
h

Silver Member

11 Followers

Sun Pharma  

Ultimately patience is paying rich dividends. Good to know Taro has shot up by more than 16%. Sun should open with a big gap monday morning. Cheers!

8.49 PM Jun 28th

anky51

Gold Member

13 Followers

Sun Pharma  

Awsome Taro....16% up at 137 !! good news coming for sun pharma as well !!

6.53 PM Jun 28th

yuvaraj1972

Gold Member

6 Followers

Sun Pharma  

dear kurken...its other way buddy they will acquire mnc`s like taro,caraco,dusa etc...list not going to stop and its a professionally managed company...stay invested...

10.27 AM May 30th

future_call
s

New Member

88 Followers

Lupin  

Guys: Hope you got benefitted by my buy call on Lupin today... all the pharma stocks buzzing Dr. Reddy, Lupin, Div lab... tomorrow sun pharma likely to post good results.. so continue buy Lupin as near term target is 960. Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro

4.06 PM May 28th

future_call
s

New Member

88 Followers

Sun Pharmaceutical Industries  

Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro Pharma contributes near 48% of US revenue and 29% of total revenue. Sharekhan expect Sun Pharma to report a revenue of Rs4290 crore (39.7% YoY)and net profit of Rs1313 crore (29.8% YoY) in Q4FY2014. Sharekhan can expect

4.03 PM May 28th

Sun Pharma  

Taro EPS up 44% for FY.

2.43 PM May 28th

Sun Pharma  

Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95 Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes Taro`s FY 14 results. EPS

2.42 PM May 28th

sumit1121

New Member

24 Followers

Sun Pharma  

Taro posted spectacular results this time around. Sun Pharma will also post good results tomorrow. Exporters are doing good currently, so it is a good idea to buy sun pharma today, a combination of good results and short covering on expiry can easily take this stock to 600 levels. 580 can be used

1.54 PM May 28th

News across the web »
Dec 15, 2014 at 08:39 | Source: FirstPost
Nov 14, 2014 at 03:51 | Source: Calcutta Telegraph News